Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)
Expression and ERG regulation of PIM kinases in prostate cancer
Julkaisun tekijät: Eerola Sini K., Kohvakka Annika, Tammela Teuvo L. J., Koskinen Päivi J., Latonen Leena, Visakorpi Tapio
Kustantaja: WILEY
Julkaisuvuosi: 2021
Journal: Cancer Medicine
Tietokannassa oleva lehden nimi: CANCER MEDICINE
Lehden akronyymi: CANCER MED-US
Volyymi: 10
Julkaisunumero: 10
Aloitussivu: 3427
Lopetussivun numero: 3436
Sivujen määrä: 10
ISSN: 2045-7634
eISSN: 2045-7634
DOI: http://dx.doi.org/10.1002/cam4.3893
Verkko-osoite: https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.3893
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/57951912
The three oncogenic PIM family kinases have been implicated in the development of prostate cancer (PCa). The aim of this study was to examine the mRNA and protein expression levels of PIM1, PIM2, and PIM3 in PCa and their associations with the MYC and ERG oncogenes. We utilized prostate tissue specimens of normal, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), untreated PCa, and castration-resistant prostate cancer (CRPC) for immunohistochemical (IHC) analysis. In addition, we analyzed data from publicly available mRNA expression and chromatin immunoprecipitation sequencing (ChIP-Seq) datasets. Our data demonstrated that PIM expression levels are significantly elevated in PCa compared to benign samples. Strikingly, the expression of both PIM1 and PIM2 was further increased in CRPC compared to PCa. We also demonstrated a significant association between upregulated PIM family members and both the ERG and MYC oncoproteins. Interestingly, ERG directly binds to the regulatory regions of all PIM genes and upregulates their expression. Furthermore, ERG suppression with siRNA reduced the expression of PIM in PCa cells. These results provide evidence for cooperation of PIM and the MYC and ERG oncoproteins in PCa development and progression and may help to stratify suitable patients for PIM-targeted therapies.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
